MEDICAMEQMedicamen Biotech Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on MEDICAMEQ — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 37/100)
- • ROE: 3.5%
- • ROCE: 3.8%
- • RSI: 34
- • MACD: bearish
Bull case
- • Debt/Equity: 0.17
- • Promoter holding: 62.5%
- • Valuation vs sector: P/E 35.5 vs sector 35.5
- • Golden cross setup: SMA50 above SMA200
Bear case
- • ROE: 3.5%
- • ROCE: 3.8%
- • RSI: 34
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • ROE: 3.5%
- • ROCE: 3.8%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹14.92). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.